Welcome to our dedicated page for Impel Pharmaceuticals news (Ticker: IMPL), a resource for investors and traders seeking the latest updates and insights on Impel Pharmaceuticals stock.
Impel Pharmaceuticals Inc. (symbol: IMPL) is a Seattle-based biopharmaceutical company dedicated to providing groundbreaking therapies for central nervous system (CNS) diseases. Their innovative approach leverages a proprietary nasal drug delivery system known as the POD™ device, which ensures consistent and predictable drug administration to the upper nasal cavity.
Impel's diverse product portfolio is focused on addressing significant unmet medical needs.
- INP104 (POD™ DHE) is in development for the acute treatment of migraine headaches.
- INP103 (POD™ Levodopa) aims to offer relief for Parkinson's disease patients.
- INP105 (POD™ Olanzapine) targets agitation associated with schizophrenia and bipolar disorders.
- INP102 (POD™ Insulin) is being tested in an NIH-funded trial for Alzheimer's disease.
In September 2021, Impel received FDA approval for Trudhesa®, a nasal spray specifically designed for the acute treatment of migraine with or without aura in adults. This marks a significant milestone in their journey to provide effective therapies for CNS conditions.
Despite recent achievements, Impel has encountered financial challenges and has filed for Chapter 11 bankruptcy as part of a strategic decision to maximize value for stakeholders. The company is actively pursuing a sale and has entered into an agreement with JN BIDCO LLC as the 'stalking horse' bidder. Throughout this process, Impel aims to continue operating normally, ensuring minimal disruption to its customers, employees, and other key stakeholders.
For more details, visit Impel Pharmaceuticals Inc.
Impel Pharmaceuticals (NASDAQ: IMPL) announced promising results from a pharmacokinetic and pharmacodynamic evaluation of Trudhesa, a nasal spray formulation of dihydroergotamine, showing no predicted drug-drug interactions (DDIs) of clinical concern when used with gepants. The analysis from the STOP 301 trial indicates that Trudhesa can be safely co-administered with preventive CGRP therapies, such as erenumab, with limited adverse events reported. Trudhesa offers rapid and sustained migraine relief, bypassing gastrointestinal metabolism and allowing use during migraine attacks. Approximately 31 million adults in the U.S. suffer from migraines, emphasizing the need for effective treatment options. Trudhesa uses Impel's proprietary Precision Olfactory Delivery technology to enhance drug absorption without injections.
Impel Pharmaceuticals (NASDAQ: IMPL) announces the appointment of Darren Cline to its Board of Directors, effective April 12, 2023. Cline, who has over 30 years of biopharmaceutical experience, replaces H. Stewart Parker, who is departing the board. Cline's prior roles include CEO at Epygenix Therapeutics and U.S. Chief Commercial Officer at GW Pharmaceuticals, where he oversaw Epidiolex's commercial activities. Cline aims to leverage his expertise to enhance the adoption and commercialization of Trudhesa in the acute migraine market, which is seeing increasing prescriptions. The company emphasizes the potential growth of Trudhesa and its innovative POD® technology, which facilitates effective drug delivery.
Impel Pharmaceuticals Highlights Trudhesa Presentations
On April 11, 2023, Impel Pharmaceuticals (NASDAQ: IMPL) announced that four abstracts featuring its Trudhesa® nasal spray will be presented at the American Academy of Neurology Annual Meeting in Boston, running from April 22-27, 2023. The presentations will cover topics such as the management of status migrainosus, drug-drug interactions with gepants, and the safety and efficacy of Trudhesa in conjunction with other treatments. Key presentation times include April 26 at 11:45 a.m. and 5:30 p.m. ET, and April 27 at 8:00 a.m. and 11:45 a.m. ET. This meeting is significant for Impel as it showcases ongoing efforts to address unmet medical needs in migraine treatment, particularly following Trudhesa's FDA approval for acute migraine treatment in adults.
Cellarity, a life sciences company, has announced several key leadership appointments to enhance its innovative drug discovery platform. John Leaman, M.D., M.B.A., joins as Chief Financial Officer, bringing extensive experience from Impel Pharmaceuticals, Selecta Biosciences, and Medgenics. Cameron Trenor, M.D., is appointed as Vice President and Head of Translational Medicine, with a strong background in hematology drug development. Anjali Kumar, Ph.D., takes on the role of Vice President, Head of Business Development, previously leading innovation at Johnson & Johnson. Additionally, Parul Doshi, M.B.A., has been promoted to Chief Data Officer. These changes aim to accelerate Cellarity's progress towards its clinical pipeline, leveraging its proprietary AI platform to create novel drug candidates for complex diseases.
FAQ
What is the market cap of Impel Pharmaceuticals (IMPL)?
What is Impel Pharmaceuticals' core focus?
What is the POD™ device?
What is Trudhesa®?
What are the current products under investigation by Impel?
What recent financial steps has Impel taken?
Who is the 'stalking horse' bidder in Impel's sale process?
Will Impel continue its operations during the sale process?
Who is advising Impel during its restructuring?
Who is Impel's current Chief Restructuring Officer?
How can stakeholders get more information about the proceedings?
